Clinuvel Pharmaceuticals logo

CUV - Clinuvel Pharmaceuticals Share Price

A$28.25 -0.8  -2.6%

Last Trade - 24/01/20

Sector
Healthcare
Size
Mid Cap
Market Cap £721.7m
Enterprise Value £693.6m
Revenue £16.5m
Position in Universe 224th / 1828
Bullish
Bearish
Unlock CUV Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CUV Revenue Unlock CUV Revenue

Net Income

CUV Net Income Unlock CUV Revenue

Normalised EPS

CUV Normalised EPS Unlock CUV Revenue

PE Ratio Range

CUV PE Ratio Range Unlock CUV Revenue

Dividend Yield Range

CUV Dividend Yield Range Unlock CUV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CUV EPS Forecasts Unlock CUV Revenue
Profile Summary

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing drugs for the treatment of a range of severe skin disorders. Its lead compound, SCENESSE (afamelanotide 16 milligrams), prevents phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company focuses at preventing the symptoms of skin diseases related to the exposure to harmful ultra violet (UV) radiation and at repigmentation of the skin due to a number of depigmentation disorders. SCENESSE has completed Phase II and III trials in the United States and Europe, and has been granted marketing authorization by the European Commission for adults with EPP. It has operations in Europe, the United States and Singapore. SCENESSE acts by increasing the levels of melanin in the skin and shields against UV radiation (UVR) and sunlight. SCENESSE is delivered via a subcutaneous dissolving implant.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated December 14, 1999
Public Since February 13, 2001
No. of Shareholders: 3,961
No. of Employees: 16
Sector Healthcare
Industry Pharmaceuticals
Index S&P/ASX All Ordinaries , S&P/ASX 200 , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 48,960,633
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address L 11 535 Bourke St, MELBOURNE, 3000, Australia
Web http://www.clinuvel.com/
Phone +61 3 96604900
Contact ()
Auditors Grant Thornton Audit Pty Ltd
CUV Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CUV
Upcoming Events for CUV
Similar to CUV
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.